Regeneron Pharmaceuticals Inc.
Budget
€100 — €0
EP Access
1
accredited persons
Staff
2
0.35 FTE
EU Grants
None
Mission & Goals
Regeneron is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, Regeneron's unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments and product candidates in development, almost all of which were homegrown in Regeneron's laboratories. Regeneron's medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. More than 15,000 of our colleagues work across the globe, with offices in 12 countries and clinical trials underway in more than 100 countries. For more information see www.regeneron.com.
EU Legislative Interests
Regeneron monitors and follows policies and initiatives related to its business, these include: Clinical Trial Regulation Medical Devices Regulation In Vitro Diagnostics Regulation EU Pharmaceutical Legislation AI Act Intellectual property Health Technology Assessment Regulation European Industrial Strategy European Health Data Space Biotech Act
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
EUCOPE Regeneron is corporate member of the Transform Alliance, the European Haemophilia Consortium and the European Federation of Allergy and Airways Diseases Patients' Associations. Regeneron also supports the SPEAK UP for COPD coalition and is a member of the steering committee.
Commissioner Meetings
No recorded meetings with EU commissioners.